IN2014DN07812A - - Google Patents
Download PDFInfo
- Publication number
- IN2014DN07812A IN2014DN07812A IN7812DEN2014A IN2014DN07812A IN 2014DN07812 A IN2014DN07812 A IN 2014DN07812A IN 7812DEN2014 A IN7812DEN2014 A IN 7812DEN2014A IN 2014DN07812 A IN2014DN07812 A IN 2014DN07812A
- Authority
- IN
- India
- Prior art keywords
- reprogramming
- methods
- marks
- epigenetic
- mark readers
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/50—Molecular design, e.g. of drugs
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/60—In silico combinatorial chemistry
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/60—In silico combinatorial chemistry
- G16C20/64—Screening of libraries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Theoretical Computer Science (AREA)
- Bioinformatics & Computational Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Computing Systems (AREA)
- Evolutionary Biology (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Library & Information Science (AREA)
- Biotechnology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261603650P | 2012-02-27 | 2012-02-27 | |
US201261637282P | 2012-04-24 | 2012-04-24 | |
PCT/CA2013/050145 WO2013127011A1 (en) | 2012-02-27 | 2013-02-27 | Reprogramming effector protein interactions to correct epigenetic defects in cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014DN07812A true IN2014DN07812A (pt) | 2015-05-15 |
Family
ID=49081499
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN7812DEN2014 IN2014DN07812A (pt) | 2012-02-27 | 2013-02-27 |
Country Status (11)
Country | Link |
---|---|
US (1) | US9552457B2 (pt) |
EP (1) | EP2819662B1 (pt) |
JP (1) | JP6137703B2 (pt) |
KR (1) | KR102149860B1 (pt) |
CN (1) | CN104136020B (pt) |
AU (1) | AU2013225592B2 (pt) |
BR (1) | BR112014021201B1 (pt) |
CA (1) | CA2865675C (pt) |
IN (1) | IN2014DN07812A (pt) |
RU (1) | RU2637441C2 (pt) |
WO (1) | WO2013127011A1 (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2672989T3 (es) * | 2013-03-15 | 2018-06-19 | Sutter Bay Hospitals | FALZ para su uso como diana para terapias para tratar el cáncer |
KR20160064121A (ko) * | 2013-09-09 | 2016-06-07 | 글리오노바 에이비 | 화합물 및 그의 암 치료를 위한 용도 |
EP3064205A1 (en) * | 2015-03-06 | 2016-09-07 | Glionova AB | Therapeutic use of isomeric forms of 2-(4-chlorophenyl)quinolin-4-yl)(piperidin-2-yl)methanol |
US20180223368A1 (en) * | 2015-03-18 | 2018-08-09 | Memorial Sloan Ketteting Cancer Center | Methods for diagnosing and treating follicular lymphoma |
WO2017021229A1 (en) | 2015-07-31 | 2017-02-09 | Sanofi-Aventis Deutschland Gmbh | Sensor, cartridge and drug delivery device |
JP2021501198A (ja) * | 2017-10-27 | 2021-01-14 | トランスフュージョン ヘルス,リミティド ライアビリティ カンパニー | フルオレンの誘導体を用いて造血幹細胞を増殖する組成物および方法 |
WO2022081892A1 (en) * | 2020-10-14 | 2022-04-21 | The Regents Of The University Of California | Systems for and methods of determining protein-protein interaction |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL263904A (pt) | 1960-04-26 | |||
GB1120463A (en) | 1964-07-06 | 1968-07-17 | Manuf Prod Pharma | Derivatives of 1,3-diazafluoranthene-1-oxide |
US3622580A (en) | 1969-03-25 | 1971-11-23 | Smith Kline French Lab | Piperazino-acetylamino-9-fluorenones and-anthraquinones |
LU85246A1 (fr) | 1984-03-13 | 1985-10-14 | R L Galephar Sa | 2-(aminoalkyl)acrylophenones,leur preparation et leur utilisation |
US5501959A (en) | 1989-01-17 | 1996-03-26 | Alamar Biosciences Laboratory, Inc. | Antibiotic and cytotoxic drug susceptibility assays using resazurin and poising agents |
EP1108055A1 (en) * | 1998-08-25 | 2001-06-20 | The Scripps Research Institute | Methods and systems for predicting protein function |
US7928218B2 (en) | 2002-02-20 | 2011-04-19 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA) |
EP2027087A2 (en) | 2006-05-18 | 2009-02-25 | MannKind Corporation | Intracellular kinase inhibitors |
WO2009015283A2 (en) * | 2007-07-24 | 2009-01-29 | President And Fellows Of Harvard College | Bhc80 - histone complexes and uses thereof |
US20110237606A1 (en) | 2008-09-26 | 2011-09-29 | Agency Of Science, Technology And Research | 3-Deazaneplanocin Derivatives |
WO2010045199A2 (en) | 2008-10-13 | 2010-04-22 | University Of South Florida | Method of modulating ship activity |
GB0822248D0 (en) | 2008-12-05 | 2009-01-14 | Medical Res Council | Crystal meths |
WO2010094009A2 (en) * | 2009-02-13 | 2010-08-19 | Children's Hospital Medical Center | Methods and compositions for the treatment of ras associated disorders |
EP2461806A4 (en) | 2009-07-31 | 2012-12-26 | Us Health | SMALL ANTI-ANGIOGENIC MOLECULES AND METHODS OF USE |
WO2011103016A2 (en) | 2010-02-19 | 2011-08-25 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting ezh2 |
DK2571503T3 (en) * | 2010-05-14 | 2015-04-20 | Dana Farber Cancer Inst Inc | COMPOSITIONS AND THEIR USE IN THE TREATMENT OF NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS |
PL2614369T3 (pl) | 2010-09-10 | 2016-08-31 | Epizyme Inc | Sposób określania przydatności inhibitorów ludzkiego ezh2 w leczeniu |
WO2012071469A2 (en) | 2010-11-23 | 2012-05-31 | Nevada Cancer Institute | Histone demethylase inhibitors and uses thereof for treatment o f cancer |
US20140066410A1 (en) | 2011-02-23 | 2014-03-06 | Icahn School Of Medicine At Mount Sinai | Inhibitors of bromodomains as modulators of gene expression |
WO2012123119A1 (en) | 2011-03-17 | 2012-09-20 | Cellzome Ag | Methods for the identification and characterization of proteins interacting with histone tails and of compounds interacting with said proteins |
WO2013059944A1 (en) * | 2011-10-28 | 2013-05-02 | British Columbia Cancer Agency Branch | Epigenetic regulators and uses thereof |
-
2013
- 2013-02-27 BR BR112014021201-5A patent/BR112014021201B1/pt not_active IP Right Cessation
- 2013-02-27 CA CA2865675A patent/CA2865675C/en active Active
- 2013-02-27 US US14/381,588 patent/US9552457B2/en active Active
- 2013-02-27 KR KR1020147027072A patent/KR102149860B1/ko active IP Right Grant
- 2013-02-27 IN IN7812DEN2014 patent/IN2014DN07812A/en unknown
- 2013-02-27 AU AU2013225592A patent/AU2013225592B2/en not_active Ceased
- 2013-02-27 CN CN201380011304.1A patent/CN104136020B/zh not_active Expired - Fee Related
- 2013-02-27 RU RU2014138543A patent/RU2637441C2/ru active
- 2013-02-27 JP JP2014557953A patent/JP6137703B2/ja not_active Expired - Fee Related
- 2013-02-27 WO PCT/CA2013/050145 patent/WO2013127011A1/en active Application Filing
- 2013-02-27 EP EP13754077.9A patent/EP2819662B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2013225592B2 (en) | 2017-11-09 |
RU2637441C2 (ru) | 2017-12-04 |
CN104136020B (zh) | 2018-08-28 |
JP6137703B2 (ja) | 2017-05-31 |
CA2865675C (en) | 2023-02-28 |
US20150154345A1 (en) | 2015-06-04 |
BR112014021201A2 (pt) | 2021-06-08 |
KR102149860B1 (ko) | 2020-08-31 |
BR112014021201B1 (pt) | 2023-01-24 |
AU2013225592A2 (en) | 2014-10-09 |
EP2819662B1 (en) | 2019-04-10 |
KR20140132382A (ko) | 2014-11-17 |
US9552457B2 (en) | 2017-01-24 |
CN104136020A (zh) | 2014-11-05 |
EP2819662A1 (en) | 2015-01-07 |
JP2015515448A (ja) | 2015-05-28 |
RU2014138543A (ru) | 2016-04-20 |
WO2013127011A1 (en) | 2013-09-06 |
EP2819662A4 (en) | 2016-03-23 |
AU2013225592A1 (en) | 2014-10-09 |
CA2865675A1 (en) | 2013-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014DN07812A (pt) | ||
PH12017501306A1 (en) | Inhibitors of histone demethylases | |
MX2015005963A (es) | Inhibidores heterociclicos de glutaminasa. | |
SG10201907164SA (en) | Rna containing composition for treatment of tumor diseases | |
NZ626618A (en) | Hydroxamic acid derivatives and uses thereof | |
MX2016001587A (es) | Inhibidores de kdm1a para el tratamiento de enfermedades. | |
IN2014DN09118A (pt) | ||
CO7141410A2 (es) | Compuesto heterocíclico nitrogenado | |
BR112015005227A2 (pt) | inibidores de glicosilceramida sintase | |
PE20151727A1 (es) | Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c | |
MX348348B (es) | Extracto de aguacate enriquecido en compuestos bioactivos con actividad antimicrobiana, antibacteriana e inhibidora de la germinacion de esporas bacterianas. | |
MX350539B (es) | Compuestos de enediino, conjugados de los mismos y sus usos y metodos. | |
MX2015000526A (es) | Cateter de globo que puede ubicarse de manera mejorada. | |
BR112016002069A2 (pt) | novo composto de pirimidina fusionada ou sal deste | |
WO2011038210A3 (en) | Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity | |
TN2013000227A1 (en) | Use of sigma ligands in bone cancer pain | |
MX2019013441A (es) | Cateter con marcas para facilitar alineacion. | |
NZ627480A (en) | Inhibitors of iap | |
BR112015018047A2 (pt) | composições estáveis que compreendem heparinoide, anestésico de ação aguda e tampão | |
BR112015021324A2 (pt) | derivados de 6-[4-(1h-imidazol-2-il)piperidin-1-il]pirimidin-4-amina como moduladores de atividade de quinase | |
MX343517B (es) | 2,4 pirimidinadiaminas sustituidas para su uso en lupus discoide. | |
BR112014003096A2 (pt) | uso de ccne2 como marcador de estratificação no tratamento de tumores de mama com inibidores de pan-cdk | |
MX2018010829A (es) | Inductores de molécula pequeña de especies de oxígeno reactivo e inhibidores de la actividad mitocondrial. | |
WO2014029888A3 (en) | Branched or macrocyclic polyamines and uses thereof | |
WO2011103028A3 (en) | Compositions and methods for inhibiting mmset |